Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 9/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702073 | 0.93 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3441594 | 0.90 | BDKRB1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3441596 | 0.90 | BDKRB1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL702190 | 0.89 | NPC1 (0.37) | BDKRB1ALDH1A1 | |
| SCHEMBL702002 | 0.88 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL703139 | 0.87 | BDKRB1 (0.39) | BDKRB1ALDH1A1 | |
| SCHEMBL10246334 | 0.87 | BDKRB1 (0.39) | BDKRB1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL704835 | 0.86 | BDKRB1 (0.38) | BDKRB1ALDH1A1 | |
| SCHEMBL701846 | 0.86 | BDKRB1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4299396 | 0.84 | BDKRB1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | PSEN1 1053/4885PSEN2 923/4885APH1B 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.